A hospital study demonstrated an average total cost saving of around $25,000 for each patient with candidemia.
The Institute for Clinical and Economic Review is seeking public comment on its plan to evaluate the cost-effectiveness of EGFR inhibitors and immunotherapies.
The group has detailed cost data, performed economic modeling, and provided cost estimation tools to help labs convey to payors the value of sequencing procedures.
A genetic testing utilization service launched by Stanford in 2015 helped cut the number of inappropriately ordered tests in half and saved about $250,000 during the first year.
Using whole-exome sequencing early in the diagnostic process could save $3,500 on average in patients who obtain a diagnosis from it and $1,700 in patients who do not.
The firms found that NGS-based carrier screening is more cost effective than genotyping-based testing for 14 disorders and results in fewer affected births.
The study found that Oncotype DX testing was associated with less frequent chemo use among women at a high clinical risk of recurrence and more frequent chemo in women considered low risk.
The latest analysis of CYP2C19 genotyping to guide antiplatelet therapy tries to address cost questions from the vantage of a payor or large healthcare system.
The NICE recommendation specifies the use of Oncotype DX for intermediate risk patients for whom doctors are unclear whether to prescribe chemotherapy.
Researchers from Myriad and elsewhere presented data on three studies involving its prostate cancer test at a medical conference.
Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.
Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.
The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.
In Science this week: genetically modified flu virus could be key to new live vaccines, and more.